Read a low % can have severe joint deterioration with this drug. Any precipitating issues to look for before this drug is prescribed. Do we know which individuals are in the higher range of this possible side effect?
Current FDA approval status, regulatory history, and clinical trial results for tanezumab, an investigational treatment for chronic pain due to osteoarthritis from the development pipeline at Pfizer Inc.
I have issues with any study for "low back pain" because in my opinion this is a garbage diagnosis. However, this is the most recent study with this medication.
This randomized, double-blind, phase 3 study (56-week treatment; 24-week follow-up) assessed tanezumab in patients with chronic low back pain and history of inadequate response to standard-of-care analgesics (NCT02528253). Patients received placebo, subcutaneous tanezumab (5 or 10 mg every 8...
"The proportion of patients with ≥50% improvement in LBPI at week 16 was 37.4% in the placebo group, 43.3% in the tanezumab 5mg group (Odds ratio [95% CI] vs placebo = 1.28 [0.97, 1.70; P=0.0846]) and 46.3% in the tanezumab 10mg group (Odds ratio [95% CI] vs placebo = 1.45 [1.09, 1.91; P=0.0101])"
Interesting, although I'm sure when this comes out it'll $10,000 per dose or something stupid which means no one will get it. I can't even get Nucynta covered.